Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
REPL
SELLReplimune Group, Inc. · Healthcare · United States · $814M · Avg Vol: $30M/d
COMPANY DESCRIPTION
Replimune Group, Inc. is a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer. Its lead product candidates are designed to selectively replicate in cancer cells and express immune-stimulating proteins, enhancing the body's anti-tumor response. The company's innovative oncolytic virus platform holds potential to address a broad range of solid tumors, positioning it in a highly specialized and rapidly evolving segment of the oncology market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | — | — | 33.5M | 69.9M | — |
| EPS | -2.26 | -2.99 | -3.24 | -3.07 | -3.38 | — | -3.47 | -1.94 | -1.15 | — |
| Shares | 47.3M | 56.7M | 61.4M | 77.1M | 82.7M | +74.7% | 83.9M | — | — | — |
| Debt | 32.8M | 60.8M | 75.9M | 76.2M | 111.6M | 35.8% | 111.6M | — | — | — |
| Equity | 411.2M | 555.3M | 374.5M | 415.8M | 166.2M | -20.3% | — | — | — | — |
| Op CF | -82.2M | -128.1M | -185.5M | -192.3M | -280.3M | — | -280.3M | — | — | — |
| Inv CF | -1.8M | -142.5M | 97.2M | -23.8M | 310.8M | — | — | — | — | — |
| Fin CF | 6.6M | 311.3M | 16.3M | 252.4M | 66.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of REPL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| REPL | Replimune Group, Inc.(you) | $814M | 29 | SELL |
| 0KCS.L | OPKO Health, Inc. | $734M | 31 | SELL |
| OMER | Omeros Corporation | $709M | 27 | SELL |
| STTK | Shattuck Labs, Inc. | $710M | 27 | SELL |
| ANL | Adlai Nortye Ltd. | $805M | 24 | SELL |
| GERN | Geron Corporation | $911M | 26 | SELL |
| DSGN | Design Therapeutics, Inc. | $736M | 25 | SELL |
| SLDB | Solid Biosciences Inc. | $771M | 24 | SELL |
| CADL | Candel Therapeutics, Inc. | $700M | 33 | SELL |
| NGNE | Neurogene Inc. | $696M | 33 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%